Skip to main content

Table 5 Comparison of patient data from visits in which EGD detected esophagitis (n = 52), respectively did not detect esophagitis (n = 125)

From: Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis

  Esophagitis
Median (Q1, Q3)
No esophagitis
Median (Q1, Q3)
p*
Age 62 (51, 69.5) 64 (56, 72) 0.086
Disease duration 10 (6, 19) 12 (7, 19) 0.487
mRSS 5 (0, 11.75) 2 (0, 6) 0.002
FVC 93.5 (76.5, 110.8) 99 (84, 108) 0.528
BMI 23.2 (21.6, 25.9) 23.8 (21.1, 28.1) 0.407
Hb 13.6 (12.4, 14.6) 12.9 (11.6, 13.7) 0.006
ESR 18 (8, 28) 16 (10, 28) 0.888
  n (%) n (%) p#
Subset of SSc Diffuse 13 (26.5)
Limited 36 (73.5)
Diffuse 24 (22)
Limited 85 (78)
0.536
Barrett’s esophagus 9 (17.3) 15 (12) 0.347
Heartburn 32 (64) 62 (50.4) 0.104
Regurgitation 13 (26) 25 (20.3) 0.414
Dysphagia 18 (36) 46 (37.4) 0.863
Vomiting 5 (10) 5 (4.1) 0.129
Esophageal symptoms 40 (81.6) 67 (60.4) 0.008
Stomach symptoms 22 (46.8) 39 (35.5) 0.163
PPI therapy 30 (57.7) 89 (72.4) 0.057
Digital ulcers 9 (27.3) 11 (15.7) 0.217
Joint contractures 16 (33.3) 32 (29.1) 0.594
UCLA GIT 2.0 subscales Median (Q1, Q3) Median (Q1, Q3) p*
Reflux 0.50 (0.25, 0.84) 0.38 (0.13, 0.88) 0.534
Distention/bloating 0.50 (0.06, 1.00) 0.75 (0.25, 1.50) 0.069
Fecal soilage 0.00 (0.00, 0.00) 0.00 (0.00, 1.00) 0.535
Diarrhea 0.00 (0.00, 0.50) 0.00 (0.00, 0.50) 0.708
Social functioning 0.17 (0.00, 0.50) 0.17 (0.00, 0.50) 0.283
Emotional wellbeing 0.00 (0.00, 0.33) 0.11 (0.00, 0.44) 0.337
Constipation 0.00 (0.00, 0.50) 0.25 (0.00, 0.75) 0.404
Total score of UCLA GIT 2.0 0.27 (0.16, 0.61) 0.37 (0.13, 0.74) 0.452
  1. Statistically significant results are highlighted in bold font. *Mann-Whitney U test, #Chi-square test
  2. mRSS modified Rodnan skin score, FVC forced vital capacity, BMI body mass index;, Hb hemoglobin, ESR erythrocyte sedimentation rate, PPI proton pump inhibitors